August 2012
-
Canadian Biotech Immune Biosolutions said it has initiated a Phase 1 clinical trial of its IBIO123 inhaled antibody therapy, which it is developing for the treatment of COVID-19. According to the company, the trial is… Read more . . .
-
Argentinian pharma company Biosidus and Crystec have announced a new deal for development of dry powder formulations of Biosidus drugs for inhaled and/or nasal delivery using Crystec’s mSAS supercritical fluid particle engineering technology. The first… Read more . . .
-
Device maker Nemera announced that it has joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) as the consortium’s 9th associate member. Other companies that have joined as associate members in the past… Read more . . .
-
United Therapeutics said that the FDA has issued a complete response letter regarding the company’s NDA for Tyvaso treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung… Read more . . .
-
According to Oyster Point Pharma, the FDA has approved the company’s Tyrvaya (OC-01) varenicline nasal spray for the treatment of dry eye disease, and Oyster Point expects to launch the nasal spray in November 2021.… Read more . . .
-
Bayer HealthCare and Meda Pharmaceuticals have filed a patent infringement suit against Apotex after Apotex submitted an ANDA for a generic version of Astepro Allergy azelastine hydrochloride nasal spray, 0.15%. The FDA approved Bayer’s NDA… Read more . . .
-
According to Liquidia Corporation, an inter partes review by the US Patent Trial and Appeal Board (PTAB) regarding US Patent No. 9,604,901, which is listed in the Orange Book as one of 7 patents covering United Therapeutics’… Read more . . .
-
Glenmark Pharmaceuticals has announced the launch of its version of Spiriva Handihaler tiotropium bromide DPI in Spain, where it will be known as Tavulus. In August 2018, Glenmark announced that it had acquired the rights… Read more . . .
-
Inhalon Biopharma and Celltrion have initiated a Phase 1 study of IN-006 inhaled regdanvimab, Inhalon said. The study is funded in part by a US Army contract worth $7 million. In July 2021, Inhalon and… Read more . . .
-
Pulmodyne and Alcove Manufacturing and Distribution have announced a new partnership for manufacturing and distribution of Alcove’s EZ-Spray intranasal mucosal atomization device and said that Pulmodyne is set to begin manufacturing and distributing EZ-Spray devices… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.